Abliva AB
Lund · Founded 2000
About Abliva AB
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Company Facts
- Founded: 2000
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $40.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2022)
- Ticker: sto:ABLI
- Website: abliva.com
- Phone: +46 (0)46-275 62 20
Industries & Categories
Biotechnology, Clinical Trials, Health Care
Social Profiles
Canonical: https://fsome.com/organization/abliva-ab-167735 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.